MX369974B - Compuestos farmaceuticos. - Google Patents

Compuestos farmaceuticos.

Info

Publication number
MX369974B
MX369974B MX2016002738A MX2016002738A MX369974B MX 369974 B MX369974 B MX 369974B MX 2016002738 A MX2016002738 A MX 2016002738A MX 2016002738 A MX2016002738 A MX 2016002738A MX 369974 B MX369974 B MX 369974B
Authority
MX
Mexico
Prior art keywords
fluorine
hydrogen
heterocyclic rings
chlorine
optionally substituted
Prior art date
Application number
MX2016002738A
Other languages
English (en)
Other versions
MX2016002738A (es
Inventor
Charles Reader John
Original Assignee
Sareum Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sareum Ltd filed Critical Sareum Ltd
Publication of MX2016002738A publication Critical patent/MX2016002738A/es
Publication of MX369974B publication Critical patent/MX369974B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/48—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)

Abstract

La invención proporciona un compuesto que es una amida de la fórmula (2): (ver fórmula2) o una sal o estereoisómero del mismo; en donde: R7 se selecciona de cloro y flúor; R3, R4, R5 y R6 son cada uno seleccionados independientemente de hidrógeno, flúor y cloro; n es 0, 1 ó 2; Q1 se selecciona de C(=0), S(=0) y SO2; A está ausente o es NR2; R1 se selecciona de: - Hidrógeno; - Un grupo hidrocarbonado no aromático C1-6 opcionalmente sustituido; y anillos carbocíclicos y heterocíclicos no aromáticos de 3 a 7 miembros que contienen uno o dos miembros de anillo heteroatómicos seleccionado de O, N y S, y anillos heterocíclicos bicíclicos puenteados de siete a nueve miembros de anillo de los cuales uno o dos son átomos de nitrógeno, los anillos carbocíclicos y heterocíclicos y los anillos heterocíclicos bicíclicos puenteados están opcionalmente sustituidos; R2 se selecciona de hidrógeno y alquilo C1-4; o NR1R2 forman un anillo heterocíclico no aromático opcionalmente sustituido de 4 a 7 miembros que contiene nitrógeno que contiene opcionalmente un segundo miembro de anillo heteroatómico seleccionado entre nitrógeno y oxígeno; con las condiciones de que: (i) no más de dos de R3 a R6 son distintos de hidrógeno; y (ii) cuando R7 y R 6 son flúor, entonces uno de R3 a R5 es cloro o flúor y/o R1-A-Q1 se selecciona del etilsulfonilo e isopropilsulfonilo. También se proporcionan composiciones farmacéuticas que contienen los compuestos y sus usos terapéuticos.
MX2016002738A 2013-09-03 2013-09-03 Compuestos farmaceuticos. MX369974B (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2013/068198 WO2015032423A1 (en) 2013-09-03 2013-09-03 Pharmaceutical compounds

Publications (2)

Publication Number Publication Date
MX2016002738A MX2016002738A (es) 2016-08-11
MX369974B true MX369974B (es) 2019-11-27

Family

ID=49237179

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016002738A MX369974B (es) 2013-09-03 2013-09-03 Compuestos farmaceuticos.

Country Status (12)

Country Link
JP (1) JP6239118B2 (es)
KR (1) KR102191084B1 (es)
CN (1) CN105793245B (es)
AU (1) AU2013399913B2 (es)
BR (1) BR112016004723B1 (es)
CA (1) CA2941824C (es)
IL (1) IL244380B (es)
MX (1) MX369974B (es)
RU (1) RU2652795C2 (es)
SG (1) SG11201601503SA (es)
WO (1) WO2015032423A1 (es)
ZA (1) ZA201602047B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201617871D0 (en) 2016-10-21 2016-12-07 Sareum Limited Pharmaceutical compounds
WO2019132654A1 (en) * 2017-12-27 2019-07-04 Erasmus University Medical Center Rotterdam Methods of treating sarcoidosis
WO2020009566A1 (en) * 2018-07-04 2020-01-09 Erasmus University Medical Center Rotterdam Methods of treating sarcoidosis
GB201816369D0 (en) * 2018-10-08 2018-11-28 Sareum Ltd Pharmaceutical compounds
BR112021021809A2 (pt) 2019-04-30 2022-01-04 Celgene Corp Terapias de combinação compreendendo os inibidores de apremilast e tyk2
GB202005114D0 (en) 2020-04-07 2020-05-20 Sareum Ltd Crystalline Forms of a Pharmaceutical Compound
EP3944859A1 (en) 2020-07-30 2022-02-02 Assistance Publique Hôpitaux de Paris Method for treating immune toxicities induced by immune checkpoint inhibitors
KR20240070634A (ko) 2021-09-30 2024-05-21 브리스톨-마이어스 스큅 컴퍼니 Tyk2 억제제에 대한 반응성을 결정하는 방법
CA3236262A1 (en) 2021-10-25 2023-05-04 Isaac Marx Tyk2 degraders and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1497536A (en) * 1973-12-17 1978-01-12 Lilly Industries Ltd 2-acylaminooxazoles methods for their preparation and their use
ATE292118T1 (de) * 1998-05-05 2005-04-15 Hoffmann La Roche Pyrazolderivative als p-38 map kinase inhibitoren
GB0709031D0 (en) * 2007-05-10 2007-06-20 Sareum Ltd Pharmaceutical compounds
JP5478488B2 (ja) 2007-06-20 2014-04-23 メルク・シャープ・アンド・ドーム・コーポレーション Ｊａｎｕｓキナーゼの阻害剤
AU2009274454A1 (en) 2008-04-21 2010-01-28 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
US8344144B2 (en) 2008-06-18 2013-01-01 Merck Sharp & Dohme Corp. Inhibitors of Janus kinases
WO2010005841A1 (en) 2008-07-09 2010-01-14 Merck & Co., Inc. Inhibitors of janus kinases
EP2166006A1 (en) * 2008-09-18 2010-03-24 Dompe' S.P.A. 2-aryl-propionic acids and derivatives and pharmaceutical compositions containing them
GB0820819D0 (en) * 2008-11-13 2008-12-24 Sareum Ltd Pharmaceutical compounds
BR112012023382A2 (pt) 2010-03-17 2018-05-15 F Hoffmann La Roche Ag T compostos, composições e métodos de uso de imidazopiridina.
EP2588105A1 (en) 2010-07-01 2013-05-08 Cellzome Limited Triazolopyridines as tyk2 inhibitors
RU2014118954A (ru) * 2011-10-12 2015-11-20 Эррэй Биофарма Инк. 5,7-ЗАМЕЩЕННЫЕ-ИМИДАЗО[1,2-c]ПИРИМИДИНЫ
US20130231340A1 (en) * 2012-03-02 2013-09-05 Sareum Limited Pharmaceutical compounds

Also Published As

Publication number Publication date
WO2015032423A1 (en) 2015-03-12
SG11201601503SA (en) 2016-03-30
CN105793245B (zh) 2018-03-20
ZA201602047B (en) 2020-12-23
BR112016004723B1 (pt) 2022-08-30
KR102191084B1 (ko) 2020-12-15
AU2013399913B2 (en) 2018-03-15
CA2941824C (en) 2020-08-25
CN105793245A (zh) 2016-07-20
JP2016529264A (ja) 2016-09-23
IL244380A0 (en) 2016-04-21
KR20160048883A (ko) 2016-05-04
MX2016002738A (es) 2016-08-11
JP6239118B2 (ja) 2017-11-29
IL244380B (en) 2018-01-31
RU2016111522A (ru) 2017-10-09
BR112016004723A2 (es) 2017-08-01
CA2941824A1 (en) 2015-03-12
AU2013399913A1 (en) 2016-03-24
RU2652795C2 (ru) 2018-05-03

Similar Documents

Publication Publication Date Title
MX2016002738A (es) Compuestos farmaceuticos.
MX2021002978A (es) Lactamas biciclicas y metodos de uso de las mismas.
CY1121599T1 (el) Νεο παραγωγο αμινης ή αλας αυτου ως παρεμποδιστες tnf αλφα
MX2019005777A (es) Compuestos de n-(3fluoropropil)-pirrolidina sustituidos novedosos, procesos para su preparacion y usos terapeuticos de los mismos.
NZ768368A (en) Modulators of cystic fibrosis transmembrane conductance regulator
MX2018009840A (es) Sulfonilureas y compuestos relacionados y sus usos.
NZ730724A (en) Novel methyl-piperidine compounds useful for inhibiting microsomal prostaglandin e2 synthase-1
CL2014003181A1 (es) Compuestos derivados de benzamidas n- sustituidas o piridinamidas n-sustituidas; composicion farmaceutica que los comprende; metodo de tratamiento; y su uso para el tratamiento de enfermedades o trastornos seleccionados de dolor, depresion y enfermedades cardiovasculares, respiratorias o psiquiatricas o combinaciones de estas.
EA201301319A1 (ru) Производные пиридин-2(1н)-она, применимые в качестве лекарственных средств для лечения миелопролиферативных нарушений, отторжения трансплантата, иммунологически обусловленных и воспалительных заболеваний
MX338041B (es) Inhibidores de demetilasa-1 especificos de lisina y su uso.
EA201690135A1 (ru) Трициклические соединения бензоксаборола и их применение
MD4583B1 (ro) Piridinone biciclice noi
MX2017009624A (es) Macrociclos de piridazinona como inhibidores de cinasas asociadas al receptor de interleucina 1(irak) y sus usos.
EA201391537A1 (ru) ЭТИНИЛЬНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ПОЛОЖИТЕЛЬНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ mGluR5
EA201790713A1 (ru) N-АЛКИЛАРИЛ-5-ОКСОАРИЛОКТАГИДРОЦИКЛОПЕНТА[c]ПИРРОЛЬНЫЕ НЕГАТИВНЫЕ АЛОСТЕРИЧЕСКИЕ МОДУЛЯТОРЫ NR2B
AR085088A1 (es) Inhibidores de histona desacetilasa y composiciones farmaceuticas que los contienen
EA201792425A1 (ru) Трициклические соединения и их применение в качестве ингибиторов фосфодиэстераз
MX2016015467A (es) Derivados de carbonitrilo como moduladores selectivos del receptor de androgenos.
MY195881A (en) Griseofulvin Compound
MX2017005422A (es) Inhibidores de histona desacetilasa y sus usos en terapia.
EA201791667A1 (ru) Соединения бензоксаборола и их применение
EA201590757A1 (ru) Новые селективные модуляторы андрогенных рецепторов
EA201691046A1 (ru) Производные этинилимидазолин-2,4-диона в качестве модуляторов метаботропного глутаматного рецептора 4 (mglur4)
CY1120880T1 (el) Δικυκλικη ενωση που περιεχει θειο
PH12015502429A1 (en) Dicarboxylic acid compound

Legal Events

Date Code Title Description
FG Grant or registration